View in EDS PDF Full Text

Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington's Disease: Are They Fit-for-Purpose for Treatment Development?

Saved in:
Bibliographic Details
Title: Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington's Disease: Are They Fit-for-Purpose for Treatment Development?
Authors: Leuchter MK; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA., Donzis EJ; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA., Cepeda C; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA., Hunter AM; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Neuromodulation Division, Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA., Estrada-Sánchez AM; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA., Cook IA; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Neuromodulation Division, Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Bioengineering, University of California Los Angeles (UCLA), Los Angeles, CA, USA., Levine MS; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA., Leuchter AF; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Neuromodulation Division, Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Source: Frontiers in neurology [Front Neurol] 2017 Mar 30; Vol. 8, pp. 91. Date of Electronic Publication: 2017 Mar 30 (Print Publication: 2017).
Publication Type: Journal Article; Review
Journal Info: Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101546899 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2295 (Print) Linking ISSN: 16642295 NLM ISO Abbreviation: Front Neurol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 28424652
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington's Disease: Are They Fit-for-Purpose for Treatment Development?
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Leuchter+MK%22">Leuchter MK</searchLink>; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Donzis+EJ%22">Donzis EJ</searchLink>; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Cepeda+C%22">Cepeda C</searchLink>; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Hunter+AM%22">Hunter AM</searchLink>; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Neuromodulation Division, Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Estrada-Sánchez+AM%22">Estrada-Sánchez AM</searchLink>; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Cook+IA%22">Cook IA</searchLink>; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Neuromodulation Division, Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Bioengineering, University of California Los Angeles (UCLA), Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Levine+MS%22">Levine MS</searchLink>; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Leuchter+AF%22">Leuchter AF</searchLink>; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Neuromodulation Division, Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101546899%22">Frontiers in neurology</searchLink> [Front Neurol] 2017 Mar 30; Vol. 8, pp. 91. <i>Date of Electronic Publication: </i>2017 Mar 30 (<i>Print Publication: </i>2017).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation%22">Frontiers Research Foundation </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101546899 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1664-2295 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216642295%22">16642295 </searchLink><i>NLM ISO Abbreviation: </i>Front Neurol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28424652
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fneur.2017.00091
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 91
    Titles:
      – TitleFull: Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington's Disease: Are They Fit-for-Purpose for Treatment Development?
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Leuchter MK
      – PersonEntity:
          Name:
            NameFull: Donzis EJ
      – PersonEntity:
          Name:
            NameFull: Cepeda C
      – PersonEntity:
          Name:
            NameFull: Hunter AM
      – PersonEntity:
          Name:
            NameFull: Estrada-Sánchez AM
      – PersonEntity:
          Name:
            NameFull: Cook IA
      – PersonEntity:
          Name:
            NameFull: Levine MS
      – PersonEntity:
          Name:
            NameFull: Leuchter AF
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 03
              Text: 2017 Mar 30
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-print
              Value: 1664-2295
          Numbering:
            – Type: volume
              Value: 8
          Titles:
            – TitleFull: Frontiers in neurology
              Type: main
ResultId 1